Xilio Therapeutics, Inc.
XLO
$0.6998
-$0.0182-2.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | 9.27M | 6.34M | 4.62M | 2.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | 9.27M | 6.34M | 4.62M | 2.36M |
| Cost of Revenue | 15.33M | 11.22M | 11.22M | 11.22M | 11.22M |
| Gross Profit | -329.00K | -1.94M | -4.87M | -6.60M | -8.86M |
| SG&A Expenses | 28.46M | 27.15M | 24.78M | 24.66M | 24.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.65M | 66.23M | 65.99M | 68.77M | 69.06M |
| Operating Income | -56.65M | -56.96M | -59.65M | -64.15M | -66.70M |
| Income Before Tax | -56.22M | -54.30M | -58.24M | -62.80M | -65.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.22 | -54.30 | -58.24 | -62.80 | -65.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.22M | -54.30M | -58.24M | -62.80M | -65.53M |
| EBIT | -56.65M | -56.96M | -59.65M | -64.15M | -66.70M |
| EBITDA | -55.02M | -55.26M | -58.00M | -62.43M | -64.91M |
| EPS Basic | -0.91 | -0.92 | -1.36 | -1.79 | -2.18 |
| Normalized Basic EPS | -0.57 | -0.57 | -0.83 | -1.10 | -1.34 |
| EPS Diluted | -0.91 | -0.92 | -1.36 | -1.79 | -2.18 |
| Normalized Diluted EPS | -0.57 | -0.57 | -0.83 | -1.10 | -1.34 |
| Average Basic Shares Outstanding | 254.67M | 246.79M | 200.01M | 162.89M | 126.95M |
| Average Diluted Shares Outstanding | 254.67M | 246.79M | 200.01M | 162.89M | 126.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |